{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:54:56Z","timestamp":1787025296195,"version":"build-2736575974"},"reference-count":38,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"0","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec id=\"j_jomb-2019-0018_s_007\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evaluation of possible relationship between platelet glutamate dehydrogenase (GDH) activity and mental state of schizophrenia patients after antipsychotic pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jomb-2019-0018_s_008\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (n = 50) with chronic paranoid schizophrenia (F20.0) initially in acute psychotic state were examined before and after a treatment course with antipsychotics. When assessing the patients\u2019 states using PANSS, the \u00bbresponder\u00ab category was attributed to those patients who had not less than 30% reduction in the score for the corresponding PANSS \u00bbsubscale\u00ab. The control group (n = 48) was age- and gender-matched with the patient group. Platelet glutamate dehydrogenase (GDH) activity was measured in patients twice, before and after the treatment course, and once in controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jomb-2019-0018_s_009\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significantly reduced GDH activity was found in patients compared with controls. The patient group was divided into two subgroups according to median GDH activity at baseline: above and below the median GDH, subgroup 1 and subgroup 2, respectively. GDH activity significantly increased from its level at baseline after antipsychotic treatment in subgroup 2. Distribution of non-responders \/ responders to antipsychotic treatment (by PANSS scores) was significantly uneven among subgroups 1 and 2. In subgroup 1, GDH activity levels significantly correlated with PANSS scores after the treatment course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jomb-2019-0018_s_010\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline platelet GDH activity might serve as a predictor of antipsychotic therapy efficacy in schizophrenia patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jomb-2019-0018","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T06:43:23Z","timestamp":1557729803000},"source":"Crossref","is-referenced-by-count":11,"title":["Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia"],"prefix":"10.5937","volume":"0","author":[{"given":"Olga K.","family":"Savushkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Tereshkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana A.","family":"Prokhorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina S.","family":"Boksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis S.","family":"Burminskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Vorobyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita A.","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnur Sh.","family":"Burbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref141","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jnr.23176","article-title":"Deregulation of glutamate dehydrogenase in human neurologic disorders","volume":"91","year":"2013","journal-title":"J Neurosci Res"},{"key":"ref261","first-page":"469\u2013506","volume-title":"Biochemical Approaches for Glutamatergic Neurotransmission. Neuromethods, 130","year":"2018"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/138161212799316244","article-title":"Glutamate and psychosis risk","volume":"18","year":"2012","journal-title":"Curr Pharm"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"44","DOI":"10.17116\/jnevro20161163144-48","article-title":"Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis","volume":"116","year":"2016","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/18715273113129990091","article-title":"Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase","volume":"12","year":"2013","journal-title":"CNS & Neurological Disorders \u2013 Drug Targets"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138920112800784961","article-title":"The glutamate hypothesis of schizophrenia: neuroimaging and drug development","volume":"13","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"ref71","first-page":"469\u2013506","volume-title":"Biochemical Approaches for Glutamatergic Neurotransmission. Neuromethods, 130","year":"2018"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0021-9258(18)97541-1","article-title":"Crystallization and kinetic properties of glutamate dehydrogenase from frog liver","volume":"240","year":"1965","journal-title":"J Biol Chem"},{"key":"ref271","first-page":"61","article-title":"Glutamine synthetase-like protein, glutamate dehydrogenase, and cytochrome c-oxidase in platelets of patients with the first episode psychosis in the course of treatment","volume":"111","year":"2011","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/15622970510029957","article-title":"Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia","volume":"7","year":"2006","journal-title":"World J Biol Psychiatry"},{"key":"ref61","article-title":"The Glutamate Dehydrogenase Pathway and Its Roles in Cell and Tissue Biology in Health and Disease","volume":"6","year":"2017","journal-title":"Biology (Basel)"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1515\/jomb-2017-0045","article-title":"The effects of education and training given to phlebotomists for reducing preanalytical errors","volume":"37","year":"2018","journal-title":"J Med Biochem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/18715273113129990091","article-title":"Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase","volume":"12","year":"2013","journal-title":"CNS & Neurological Disorders \u2013 Drug Targets"},{"key":"ref131","first-page":"53","article-title":"Multiple forms of glutamate dehydrogenase in animals: structural determinants and physiological implications","volume":"5","year":"2016","journal-title":"Biology (Basel)"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/15622970510029957","article-title":"Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia","volume":"7","year":"2006","journal-title":"World J Biol Psychiatry"},{"key":"ref321","first-page":"53","article-title":"Multiple forms of glutamate dehydrogenase in animals: structural determinants and physiological implications","volume":"5","year":"2016","journal-title":"Biology (Basel)"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0278-5846(01)00273-1","article-title":"Diversity of glutamate dehydrogenase in human brain","volume":"26","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0278-5846(01)00273-1","article-title":"Diversity of glutamate dehydrogenase in human brain","volume":"26","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.biocel.2013.08.004","article-title":"Glutamate release from platelets: exocytosis versus glutamate transporter reversal","volume":"45","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s007020070007","article-title":"Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis-a study of potential pathogenetic mechanisms in neurodegenerative diseases","volume":"107","year":"2000","journal-title":"J Neural Transm (Vienna)"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0021-9258(18)97541-1","article-title":"Crystallization and kinetic properties of glutamate dehydrogenase from frog liver","volume":"240","year":"1965","journal-title":"J Biol Chem"},{"key":"ref251","article-title":"The Glutamate Dehydrogenase Pathway and Its Roles in Cell and Tissue Biology in Health and Disease","volume":"6","year":"2017","journal-title":"Biology (Basel)"},{"key":"ref81","first-page":"61","article-title":"Glutamine synthetase-like protein, glutamate dehydrogenase, and cytochrome c-oxidase in platelets of patients with the first episode psychosis in the course of treatment","volume":"111","year":"2011","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"44","DOI":"10.17116\/jnevro20161163144-48","article-title":"Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis","volume":"116","year":"2016","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref21","first-page":"151","article-title":"Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis","volume":"4","year":"2013","journal-title":"Front Psychiatry"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.03.035","article-title":"Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy","volume":"161","year":"2015","journal-title":"Schizophrenia Research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.03.035","article-title":"Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy","volume":"161","year":"2015","journal-title":"Schizophrenia Research"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jnr.23176","article-title":"Deregulation of glutamate dehydrogenase in human neurologic disorders","volume":"91","year":"2013","journal-title":"J Neurosci Res"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1515\/jomb-2017-0045","article-title":"The effects of education and training given to phlebotomists for reducing preanalytical errors","volume":"37","year":"2018","journal-title":"J Med Biochem"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s007020070007","article-title":"Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis-a study of potential pathogenetic mechanisms in neurodegenerative diseases","volume":"107","year":"2000","journal-title":"J Neural Transm (Vienna)"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.biocel.2013.08.004","article-title":"Glutamate release from platelets: exocytosis versus glutamate transporter reversal","volume":"45","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/138161212799316244","article-title":"Glutamate and psychosis risk","volume":"18","year":"2012","journal-title":"Curr Pharm"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138920112800784961","article-title":"The glutamate hypothesis of schizophrenia: neuroimaging and drug development","volume":"13","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"ref211","first-page":"151","article-title":"Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis","volume":"4","year":"2013","journal-title":"Front Psychiatry"}],"container-title":["Journal of Medical Biochemistry"],"original-title":[],"link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jomb\/ahead-of-print\/article-10.2478-jomb-2019-0018.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2020\/1452-82582001054S.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T18:43:55Z","timestamp":1663440235000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/article.aspx?artid=1452-82582001054S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":38,"journal-issue":{"issue":"0"},"URL":"https:\/\/doi.org\/10.2478\/jomb-2019-0018","relation":{},"ISSN":["1452-8266"],"issn-type":[{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,11]]}}}